Fig. 1 · Structure

Documents & Downloads

IOX 2

Cat. No. A11924 CAS 931398-72-0

HIF-PHD inhibitor

IOX2 is a potent inhibitor of HIF-1α prolyl hydroxylase-2 (PHD2) with IC50 of 21 nM in a cell-free assay, >100-fold selectivity over JMJD2A, JMJD2C, JMJD2E, JMJD3, or the 2OG oxygenase FIH.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

IOX2 competes with 2-oxoglutarate for PHD2 binding. In a purified-protein NMR assay, IOX2 displaced labeled 2-oxoglutarate without detectable displacement of the HIF1α CODD substrate reporter. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
PHD2 (Cell-free assay) 21 nM

In Vitro Studies

In C28/I2 human articular chondrocytes, IOX2 increased DOT1L mRNA in a concentration-dependent manner and increased DOT1L protein and H3K79 methylation signals. [2]

In normoxic HEK293T cells, 50 μM IOX2 increased HIF protein signals but did not increase small extracellular-vesicle release after 8 or 24 h. HIF stabilization therefore did not reproduce this hypoxic response under the tested conditions. [3]

PHD2 co-substrate displacement by IOX2

Biochemical assay · Purified apo-PHD2 with Zn(II), labeled 2OG or HIF1α CODD reporter [1]

IOX2 displaced 2OG but did not detectably displace CODD. The experiment supports binding at the co-substrate site while permitting substrate association.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Displacement of labeled 2OG and CODDQualitative binding competition 2OG displaced; CODD not displaced within detection limits. Error bars: SD from three separate measurements.[1]

Literature-Reported Treatment Conditions

Treatment concentration
400 μM competitor IOX2; typical assay: 50 μM apo-PHD2, 400 μM Zn(II), 50 μM labeled reporter.
Method
Selective 1H–13C 1D-HSQC displacement assay at 298 K.
Co-treatment
IOX2 alone; comparator treatments are separate arms.
Reported limits
Incubation time and IOX2 stock solvent are not specified in the NMR methods. These are binding conditions, not a catalytic IC50 assay.
Methods and source locations

Compound reported in the paper: IOX2; Compound label in the paper: IOX2

Compound-level evidence only; no Adooq supplier, lot or formulation equivalence established.

Results: IOX4 inhibits PHD2 via binding to the 2OG binding site; S3 Figure A; Methods: NMR experiments

Displacement of labeled 2OG and CODD: Reporter intensity compared with protein-containing no-inhibitor and no-protein blanks; BNS and unlabeled peptides provide comparator controls. No exact percentage inferred from bars. — S3 Figure A and caption; Methods: NMR experiments

DOT1L and H3K79 methylation in chondrocytes

Cell-based study · Human immortalized articular chondrocytes C28/I2 [2]

IOX2 increased DOT1L expression in a concentration-dependent manner and increased DOT1L protein and H3K79me2 signals in the reported assays.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
DOT1L mRNA responseGeneralized least squares concentration-response association pseudo-R² = 0.73, P < 0.0001[2]
H3K79me2 fluorescence and DOT1L proteinQualitative protein response and reported fluorescence association Increased DOT1L/H3K79me2 protein signals; H3K79 methylation fluorescence pseudo-R² = 0.97, P < 0.0001.[2]

Literature-Reported Treatment Conditions

Treatment concentration
qPCR: 0.1, 1, 10, 20 and 50 μM; protein and immunofluorescence panels: 20 and 50 μM.
Exposure duration
qPCR and immunofluorescence: 72 h; immunoblot: 96 h.
Method
Cell treatment followed by qPCR, immunoblotting or immunofluorescence.
Vehicle
DMSO
Co-treatment
IOX2 alone; comparator treatments are separate arms.
Reported limits
Panel 3A independent biological n is not specified in its caption; no n inferred from plotted replicate points. Stock concentration not supplied in the read sections.
Methods and source locations

Compound reported in the paper: IOX2; Compound label in the paper: IOX2

Compound-level evidence only; no Adooq supplier, lot or formulation equivalence established.

Figure 3A,D–F and caption; Results: Hypoxia increases DOT1L expression and H3K79 methylation in hACs; Methods: Materials, Quantitative PCR, Western blotting, Immunofluorescence

DOT1L mRNA response: qPCR normalized to S29; 72 h; vehicle comparator; caption states Holm correction for 16 tests across panels A and B. — Results corresponding to Figure 3A; Figure 3A image/caption; Methods: Quantitative PCR and Statistics

H3K79me2 fluorescence and DOT1L protein: Immunoblot images representative of 2 independent experiments. Fluorescence: 3 independent experiments, technical duplicates, 20 images/condition/experiment; mean ± SEM; image count is not biological n. — Figure 3D–F and caption; corresponding Results; Methods: Immunofluorescence

HIF stabilization without increased small EV release

Cell-based study · HEK293T cells in normoxia, with vehicle and 1% O₂ hypoxia comparators [3]

IOX2 increased HIF protein signals without increasing small extracellular-vesicle release at 8 or 24 h. Hypoxia increased EV release at 24 h.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Small EV release despite HIF protein stabilizationQualitative response with reported replication No detected increase in small EV release with IOX2 at 8 or 24 h; HIF1α/HIF2α protein signals increased. Hypoxia comparator increased small EV release at 24 h.[3]

Literature-Reported Treatment Conditions

Treatment concentration
50 μM
Exposure duration
8 h or 24 h
Method
IOX2 cell treatment in DMEM with 2% EV-free FBS; immunoblotting and nanoparticle tracking analysis.
Vehicle
0.1% DMSO
Co-treatment
IOX2 alone; comparator treatments are separate arms.
Reported limits
No exact numerical EV fold change or confidence interval extracted from plotted bars. A lack of detected increase is not an equivalence test.
Methods and source locations

Compound reported in the paper: IOX2; Compound label in the paper: IOX2

Compound-level evidence only; no Adooq supplier, lot or formulation equivalence established.

Results: Chemical inhibition of PHD2 does not affect small EV release in normoxic conditions; Figure 6a–b and caption; Methods: Reagents, EV analysis, Statistical analysis

Small EV release despite HIF protein stabilization: Figure 6a: immunoblot with β-tubulin loading control. Figure 6b: NTA on clarified conditioned medium, normalized to total cellular protein and vehicle mean. N = 3 independent experiments, each in triplicate; mean ± SEM; one-way ANOVA with Dunnett comparisons. — Figure 6a–b and caption; corresponding Results; Methods: Isolation of extracellular vesicles and analysis

In Vivo Studies

A single intraperitoneal IOX2 dose of 37.7 mg/kg increased peripheral HIF1α/HIF2α signals in mice at 1 h, while brain induction was not detected under the same condition. [1]

In a mouse DMM osteoarthritis model, intra-articular IOX2 reduced cartilage damage and osteophyte scores and increased cartilage HIF1A, DOT1L and H3K79me2 staining. The synovial inflammation comparison did not reach statistical significance (P = 0.08). [2]

Acute tissue HIF response in mice

Animal study · Male C57BL/6 mice, 3 months old; liver, kidney, heart and brain [1]

IOX2 increased peripheral HIF1α/HIF2α signals, while brain induction was not detected under the tested condition. IOX4 produced brain induction in the comparator arm.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
HIF1α and HIF2α abundance across tissuesQualitative immunoblot response Peripheral induction in liver, kidney and heart; no detectable brain induction with IOX2 at 37.7 mg/kg after 1 h.[1]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Single injection
Treatment course
Tissues collected at 1 h
Vehicle
Hanks’ buffered saline, pH 7.0, with 5% DMSO final.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
IOX2 single-dose tissue comparison
37.7 mg/kg
Vehicle; separate IOX4 (35 mg/kg) and DMOG (75 mg/kg) comparator arms.Peripheral HIF1α/HIF2α induction; brain induction not detected.[1]
IOX2 single-dose tissue comparison
Model: Male C57BL/6 mice, 3 months old; liver, kidney, heart and brain
Reported limits: Figure 4A biological n not stated in the read material; detection-limit result does not establish absence of brain penetration.
Methods and source locations

Compound reported in the paper: IOX2; Compound label in the paper: IOX2

Compound-level evidence only; no Adooq supplier, lot or formulation equivalence established.

Figure 4A and caption; Results: HIFα proteins are upregulated in tissues of mice treated with IOX4; Methods: Experiments in mice

HIF1α and HIF2α abundance across tissues: HIF1α/HIF2α immunoblots with β-actin loading control and vehicle, IOX4 and DMOG comparator lanes. — Figure 4A and caption; Results mouse comparison

IOX2 single-dose tissue comparison · Figure 4A; Methods: Experiments in mice

Local IOX2 treatment in a mouse osteoarthritis model

Animal study · Male wild-type C57BL/6 mice; DMM at 8 weeks of age; sham-operated and DMM vehicle controls [2]

Repeated intra-articular IOX2 reduced cartilage damage and osteophyte scores after DMM. Synovial inflammation did not reach statistical significance. HIF1A, DOT1L and H3K79me2 staining increased relative to DMM vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cartilage damage, osteophytes and synovial inflammationReported effect size r with 95% CI and P Cartilage: r = 0.578 [95% CI, 0.16–0.82], P = 0.021; osteophytes: r = 0.567 [95% CI, 0.13–0.82], P = 0.027; inflammation: r = 0.527 [95% CI, 0.10–0.82], P = 0.08.[2]
Cartilage HIF1A, DOT1L and H3K79me2 immunostainingReported difference of means in relative intensity HIF1A: 1.62 [95% CI, 1.24–2.10], P = 0.001; DOT1L: 3.41 [95% CI, 1.75–6.63], P = 0.001; H3K79 methylation: 3.24 [95% CI, 2.25–4.67], P < 0.0001.[2]

Conditions shared by the study groups

Route
Intra-articular
Frequency
Every 10 days
Treatment course
7 injections, beginning 1 week after DMM; endpoint 12 weeks after surgery.
Vehicle
30% PEG400 in PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
DMM with IOX2
0.5 mg/kg
DMM vehicle; sham vehicle.Reduced cartilage and osteophyte scores; inflammation comparison P = 0.08. Increased HIF1A, DOT1L and H3K79me2 staining.[2]
DMM with IOX2
Model: Male wild-type C57BL/6 mice; DMM at 8 weeks of age; sham-operated and DMM vehicle controls
Reported limits: No inference of human efficacy; histology and immunostaining have different stated sample sizes.
Methods and source locations

Compound reported in the paper: IOX2; Compound label in the paper: IOX2

Compound-level evidence only; no Adooq supplier, lot or formulation equivalence established.

Figure 6A–G and caption; Results: Intra-articular treatment with IOX2; Methods: DMM mouse model, Intra-articular IOX2 injections, Histology, Immunohistochemistry, Statistics

Cartilage damage, osteophytes and synovial inflammation: OARSI and histological scores; n = 6 sham vehicle, n = 8 each DMM vehicle and DMM IOX2. Kruskal-Wallis followed by Holm-Bonferroni-corrected pairwise Wilcoxon tests in Methods. Effect-size CIs bootstrap-based. — Figure 6B–D and caption; corresponding Results; Methods: Statistics

Cartilage HIF1A, DOT1L and H3K79me2 immunostaining: n = 5 mice/group, average of 2 technical replicates/mouse; staining relative to sham vehicle; mean ± SEM. Caption: one-way ANOVA with Šidák correction for 3 tests. Retains authors’ metric terminology; no reinterpretation as absolute intensity units. — Results corresponding to Figure 6E–G; Figure 6 caption; Methods: Immunohistochemistry

DMM with IOX2 · Figure 6A–G; Methods: Intra-articular IOX2 injections

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 931398-72-0
Applications HIF-PHD inhibitor
Formula C19H16N2O5
Molecular Weight 352.3
SMILES
C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=C(C2=O)C(=O)NCC(=O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 7 mg/mL (19.86 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
1 mg/mL
Vehicle
5% DMSO+30% PEG 300+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Mun Chiang Chan, Onur Atasoylu, Emma Hodson, et al. Potent and Selective Triazole-Based Inhibitors of the Hypoxia-Inducible Factor Prolyl-Hydroxylases with Activity in the Murine Brain PLoS ONE (2015). PMID: 26147748 DOI: 10.1371/journal.pone.0132004 Source material
  2. [2] Hypoxia induces DOT1L in articular cartilage to protect against osteoarthritis JCI Insight (2021). PMID: 34727094 DOI: 10.1172/jci.insight.150451 Source material
  3. [3] Ana Muñiz-García, Montserrat Romero, Juan Manuel Falcόn-Perez, et al. Hypoxia-induced HIF1α activation regulates small extracellular vesicle release in human embryonic kidney cells Scientific Reports (2022). PMID: 35087095 DOI: 10.1038/s41598-022-05161-7 Source material

Publications

1 publication citing this product

Added to your cart

View Cart Checkout
Loading...